Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Compare

817 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SLNO Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Soleno

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SLNO Stock 12 Month Forecast

Average Price Target

$119.60

▲(118.49% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $119.60 with a high forecast of $145.00 and a low forecast of $106.00. The average price target represents a 118.49% change from the last price of $54.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","146":"$146","68.75":"$68.8","94.5":"$94.5","120.25":"$120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$106.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,68.75,94.5,120.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.22,73.20307692307692,79.18615384615384,85.16923076923077,91.15230769230769,97.13538461538461,103.11846153846153,109.10153846153847,115.08461538461538,121.06769230769231,127.05076923076922,133.03384615384616,139.0169230769231,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.22,71.24923076923076,75.27846153846154,79.3076923076923,83.33692307692307,87.36615384615385,91.39538461538461,95.42461538461538,99.45384615384614,103.48307692307692,107.51230769230769,111.54153846153847,115.57076923076923,{"y":119.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.22,70.20307692307692,73.18615384615384,76.16923076923077,79.15230769230769,82.13538461538461,85.11846153846153,88.10153846153847,91.08461538461538,94.06769230769231,97.05076923076922,100.03384615384616,103.01692307692308,{"y":106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$145.00

Average Price Target$119.60

Lowest Price Target$106.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$110

Buy

100.95%

Upside

Reiterated

09/17/25

Soleno Therapeutics (SLNO) Gets a Buy from H.C. Wainwright

Derek Archila

Wells Fargo

$123

Buy

124.70%

Upside

Reiterated

09/11/25

Wells Fargo would be buyers of Soleno amid FAERS update weaknessWells Fargo would be buyers of Soleno amid FAERS update weakness

James Condulis

Stifel Nicolaus

$118

Buy

115.56%

Upside

Reiterated

09/11/25

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

Tyler Van Buren

TD Cowen

$115→$120

Buy

119.22%

Upside

Reiterated

09/10/25

Soleno Therapeutics (SLNO) Gets a Buy from TD Cowen

Brian Skorney

Robert W. Baird

$121

Buy

121.04%

Upside

Reiterated

09/10/25

Robert W. Baird Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)Baird analyst Brian Skorney reiterated an Outperform rating and $121.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

Kate Dellorusso

LifeSci Capital

Not Ranked

LifeSci Capital

$120

Buy

119.22%

Upside

Reiterated

09/10/25

LifeScience Cap's Optimistic Outlook on Soleno Therapeutics: Vykat XR's Promising Market Potential and Expansion PlansWe are assuming coverage of SLNO with an Outperform rang, $120 PT. In late March, the FDA approved Vykat XR (diazoxide choline extended-release [DCCR]) for the treatment of hyperphagia associated with Prader Willi syndrome (PWS), a debilitang disease marked by the insaable desire to eat. Early launch metrics point to robust uptake by paents and physicians: Q2 net sales of $32.7M, 646 start forms, and 295 new prescribers in just the ﬁrst quarter of launch. Market access is building quickly (~1/3 covered lives in the U.S.), and we expect connued growth as familiarity with the product proﬁle and reimbursement improves.

Leland Gershell

Oppenheimer

$110

Buy

100.95%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (NASDAQ: SLNO) and Hinge Health, Inc. Class A (NYSE: HNGE)We reiterate Outperform and would take advantage of the recent weakness following the short report.

Yasmeen Rahimi

Piper Sandler

$145

Buy

164.89%

Upside

Reiterated

08/21/25

Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $145.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

Kristen Kluska

Cantor Fitzgerald

$123

Buy

124.70%

Upside

Reiterated

08/19/25

Cantor Fitzgerald Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $123.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

93.64%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

91.82%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$110

Buy

100.95%

Upside

Reiterated

09/17/25

Soleno Therapeutics (SLNO) Gets a Buy from H.C. Wainwright

Derek Archila

Wells Fargo

$123

Buy

124.70%

Upside

Reiterated

09/11/25

Wells Fargo would be buyers of Soleno amid FAERS update weaknessWells Fargo would be buyers of Soleno amid FAERS update weakness

James Condulis

Stifel Nicolaus

$118

Buy

115.56%

Upside

Reiterated

09/11/25

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

Tyler Van Buren

TD Cowen

$115→$120

Buy

119.22%

Upside

Reiterated

09/10/25

Soleno Therapeutics (SLNO) Gets a Buy from TD Cowen

Brian Skorney

Robert W. Baird

$121

Buy

121.04%

Upside

Reiterated

09/10/25

Robert W. Baird Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)Baird analyst Brian Skorney reiterated an Outperform rating and $121.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

Kate Dellorusso

LifeSci Capital

Not Ranked

LifeSci Capital

$120

Buy

119.22%

Upside

Reiterated

09/10/25

Leland Gershell

Oppenheimer

$110

Buy

100.95%

Upside

Reiterated

08/25/25

Yasmeen Rahimi

Piper Sandler

$145

Buy

164.89%

Upside

Reiterated

08/21/25

Kristen Kluska

Cantor Fitzgerald

$123

Buy

124.70%

Upside

Reiterated

08/19/25

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

93.64%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

91.82%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Soleno Therapeutics

1 Month

xxx

Success Rate

12/24 ratings generated profit

Average Return

+23.55%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +23.55% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+89.75%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +89.75% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

7/10 ratings generated profit

Average Return

+181.57%

reiterated a buy rating last month

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +181.57% per trade.

2 Years

xxx

Success Rate

7/10 ratings generated profit

Average Return

+176.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +176.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLNO Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SLNO has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLNO average Analyst price target in the past 3 months is 119.60.

Each month's total comprises the sum of three months' worth of ratings.

SLNO Financial Forecast

SLNO Earnings Forecast

Next quarter’s earnings estimate for SLNO is $0.04 with a range of -$0.28 to $0.37. The previous quarter’s EPS was -$0.09. SLNO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year SLNO has Outperformed its overall industry.

SLNO Sales Forecast

Next quarter’s sales forecast for SLNO is $45.27M with a range of $35.00M to $57.99M. The previous quarter’s sales results were $32.66M. SLNO beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year SLNO has Outperformed its overall industry.

SLNO Stock Forecast FAQ

What is SLNO’s average 12-month price target, according to analysts?

Based on analyst ratings, Soleno Therapeutics Inc’s 12-month average price target is 119.60.

What is SLNO’s upside potential, based on the analysts’ average price target?

Soleno Therapeutics Inc has 118.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SLNO a Buy, Sell or Hold?

Soleno Therapeutics Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Soleno Therapeutics Inc’s price target?

The average price target for Soleno Therapeutics Inc is 119.60. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $145.00 ,the lowest forecast is $106.00. The average price target represents 118.49% Increase from the current price of $54.74.

What do analysts say about Soleno Therapeutics Inc?

Soleno Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of SLNO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

SLNO Analyst Ratings

SLNO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Soleno Therapeutics

SLNO Analyst Recommendation Trends

SLNO Financial Forecast

SLNO Earnings Forecast

SLNO Sales Forecast

SLNO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts